Ergomed plc Exercise of Share Options and Total Voting Rights (9698E)
01 Noviembre 2022 - 10:16AM
UK Regulatory
TIDMERGO
RNS Number : 9698E
Ergomed plc
01 November 2022
PRESS RELEASE
Exercise of Share Options and Total Voting Rights
Guildford, UK - 1 November 2022: Ergomed plc (LSE: ERGO)
("Ergomed" or the "Company") announces that, following an exercise
of share options, application has been made to AIM for the
admission of 70,000 new ordinary shares of 1p each in the capital
of the Company (the "New Ordinary Shares").
Admission to trading on AIM of the New Ordinary Shares
("Admission") is expected to occur on 4 November 2022. Following
Admission, the New Ordinary Shares will rank pari passu in all
respects with the Company's existing ordinary shares.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 50,085,405. This figure may be used
by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the Company under the
Financial Conduct Authority's Disclosure Guidance and Transparency
Rules.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets &
Strategy)
Numis Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO) and mission-critical regulatory compliance and consulting
services under the ADAMAS brand. For further information,
visit: http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBBBFTMTBMBIT
(END) Dow Jones Newswires
November 01, 2022 12:16 ET (16:16 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024